$4.06
-0.05-1.22%
At close: -
$4.13
0.071.72%
After Hours: Apr 10, 4:13 PM EDT
Comments
Loading...
Kezar Life Sciences Analyst Ratings and Price Targets | NASDAQ:KZR | Benzinga
Kezar Life Sciences Inc has a consensus price target of $9 based on the ratings of 4 analysts. The high is $9 issued by Wells Fargo on December 19, 2024. The low is $9 issued by Wells Fargo on December 19, 2024. The 3 most-recent analyst ratings were released by Wells Fargo, Wells Fargo, and HC Wainwright & Co. on December 19, 2024, November 14, 2024, and August 14, 2024, respectively. With an average price target of $9 between Wells Fargo, Wells Fargo, and HC Wainwright & Co., there's an implied 117.92% upside for Kezar Life Sciences Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
Wells Fargo
1calculated from analyst ratings
Analyst Ratings for Kezar Life Sciences
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 12/19/2024 | Buy Now | 117.92% | Wells Fargo | Derek Archila58% | $11 → $9 | Maintains | Equal-Weight | Get Alert |
| 12/02/2024 | Buy Now | — | HC Wainwright & Co. | Raghuram Selvaraju41% | — | Reiterates | Neutral → Neutral | Get Alert |
| 11/14/2024 | Buy Now | 166.34% | Wells Fargo | Derek Archila58% | $20 → $11 | Maintains | Equal-Weight | Get Alert |
| 10/18/2024 | Buy Now | — | HC Wainwright & Co. | Raghuram Selvaraju41% | — | Reiterates | → Neutral | Get Alert |
| 10/14/2024 | Buy Now | — | HC Wainwright & Co. | Raghuram Selvaraju41% | — | Reiterates | → Neutral | Get Alert |
| 10/02/2024 | Buy Now | — | HC Wainwright & Co. | Raghuram Selvaraju41% | — | Downgrade | Buy → Neutral | Get Alert |
| 08/14/2024 | Buy Now | 69.49% | HC Wainwright & Co. | Raghuram Selvaraju41% | $70 → $70 | Reiterates | Buy → Buy | Get Alert |
| 07/22/2024 | Buy Now | 69.49% | HC Wainwright & Co. | Raghuram Selvaraju41% | $200 → $70 | Maintains | Buy | Get Alert |
| 05/10/2024 | Buy Now | 384.26% | HC Wainwright & Co. | Raghuram Selvaraju41% | $200 → $200 | Reiterates | Buy → Buy | Get Alert |
| 03/15/2024 | Buy Now | 384.26% | HC Wainwright & Co. | Raghuram Selvaraju41% | $200 → $200 | Reiterates | Buy → Buy | Get Alert |
| 12/04/2023 | Buy Now | 384.26% | HC Wainwright & Co. | Raghuram Selvaraju41% | → $200 | Reiterates | Buy → Buy | Get Alert |
| 11/27/2023 | Buy Now | 384.26% | HC Wainwright & Co. | Raghuram Selvaraju41% | → $200 | Reiterates | Buy → Buy | Get Alert |
| 11/14/2023 | Buy Now | -51.57% | Wells Fargo | Derek Archila58% | $40 → $20 | Maintains | Equal-Weight | Get Alert |
| 10/12/2023 | Buy Now | 384.26% | HC Wainwright & Co. | Raghuram Selvaraju41% | → $200 | Reiterates | Buy → Buy | Get Alert |
| 10/05/2023 | Buy Now | — | JonesTrading | Catherine Novack24% | — | Downgrade | Buy → Hold | Get Alert |
| 09/25/2023 | Buy Now | 384.26% | HC Wainwright & Co. | Raghuram Selvaraju41% | $180 → $200 | Maintains | Buy | Get Alert |
| 08/11/2023 | Buy Now | — | Wells Fargo | Derek Archila58% | — | Downgrade | Overweight → Equal-Weight | Get Alert |
| 08/11/2023 | Buy Now | 335.84% | HC Wainwright & Co. | Raghuram Selvaraju41% | $190 → $180 | Maintains | Buy | Get Alert |
| 05/12/2023 | Buy Now | 360.05% | HC Wainwright & Co. | Raghuram Selvaraju41% | $210 → $190 | Maintains | Buy | Get Alert |
| 05/12/2023 | Buy Now | 214.77% | Wells Fargo | Derek Archila58% | $140 → $130 | Maintains | Overweight | Get Alert |
| 03/16/2023 | Buy Now | — | William Blair | Matt Phipps22% | — | Downgrade | Outperform → Market Perform | Get Alert |
| 03/16/2023 | Buy Now | 408.47% | HC Wainwright & Co. | Raghuram Selvaraju41% | → $210 | Reiterates | → Buy | Get Alert |
| 01/03/2023 | Buy Now | 238.98% | Wells Fargo | Derek Archila58% | $170 → $140 | Maintains | Overweight | Get Alert |
| 08/12/2022 | Buy Now | 408.47% | HC Wainwright & Co. | Raghuram Selvaraju41% | $200 → $210 | Maintains | Buy | Get Alert |
| 06/28/2022 | Buy Now | 311.62% | Wells Fargo | Derek Archila58% | $130 → $170 | Maintains | Overweight | Get Alert |
| 05/13/2022 | Buy Now | 214.77% | Wells Fargo | Derek Archila58% | $140 → $130 | Maintains | Overweight | Get Alert |
| 05/04/2022 | Buy Now | 238.98% | Wells Fargo | Derek Archila58% | $190 → $140 | Maintains | Overweight | Get Alert |
FAQ
What is the target price for Kezar Life Sciences (KZR) stock?
The latest price target for Kezar Life Sciences (NASDAQ:KZR) was reported by Wells Fargo on December 19, 2024. The analyst firm set a price target for $9.00 expecting KZR to rise to within 12 months (a possible 117.92% upside). 9 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Kezar Life Sciences (KZR)?
The latest analyst rating for Kezar Life Sciences (NASDAQ:KZR) was provided by Wells Fargo, and Kezar Life Sciences maintained their equal-weight rating.
When was the last upgrade for Kezar Life Sciences (KZR)?
There is no last upgrade for Kezar Life Sciences
When was the last downgrade for Kezar Life Sciences (KZR)?
The last downgrade for Kezar Life Sciences Inc happened on October 2, 2024 when HC Wainwright & Co. changed their price target from N/A to N/A for Kezar Life Sciences Inc.
When is the next analyst rating going to be posted or updated for Kezar Life Sciences (KZR)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Kezar Life Sciences, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Kezar Life Sciences was filed on December 19, 2024 so you should expect the next rating to be made available sometime around December 19, 2025.
Is the Analyst Rating Kezar Life Sciences (KZR) correct?
While ratings are subjective and will change, the latest Kezar Life Sciences (KZR) rating was a maintained with a price target of $11.00 to $9.00. The current price Kezar Life Sciences (KZR) is trading at is $4.13, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.